Navigation Links
Bausch + Lomb adquirirá Technolas Perfect Vision GmbH
Date:11/7/2012

ROCHESTER, Nueva York, y MÚNICH, 7 de noviembre del 2012 /PRNewswire/ -- Bausch + Lomb, empresa mundial de salud ocular, anunció hoy que ha ejercido su opción para adquirir todas las acciones en circulación y sin titulares de Technolas™ Perfect Vision GmbH (TPV), empresa líder de láser oftalmológico. Technolas Perfect Vision fue creada en el 2009 a través de un acuerdo empresario entre Bausch + Lomb y 20/10 PERFECT VISION AG para desarrollar y vender tecnologías avanzadas refractivas y de cataratas. Se espera que el acuerdo se cierre a fines de enero del 2013.

Bausch + Lomb y Technolas Perfect Vision suscribieron un acuerdo de promoción conjunta en septiembre del 2011, que también incluyó una opción para Bausch + Lomb de adquirir la empresa si se lograban ciertas metas. Desde ese momento, las empresas han aprovechado sus conocimientos refractivos y de cataratas combinados y sus capacidades comerciales para promover y fomentar el láser de femtosegundo VICTUS™, que es capaz de soportar intervenciones de cataratas y de córneas en una sola plataforma. En los últimos doce meses, la plataforma VICTUS recibió la aprobación de comercialización de las autoridades regulatorias de Europa y los Estados Unidos, y las empresas siguen presentando registraciones en otras partes del mundo al tiempo que aceleran la implementación.

"Nuestra adquisición de Technolas Perfect Vision representa un hito importante para Bausch + Lomb, pero tal vez sea más importante marcar lo que significa para los pacientes refractivos y de cataratas de todo el mundo", afirmó Brent Saunders, presidente y director ejecutivo de Bausch + Lomb. "El equipo de Technolas Perfect Vision ha creado una gran empresa y, desde mi perspectiva, los láseres oftálmicos más innovadores del sector".

"Nuestros sis
'/>"/>

SOURCE Bausch + Lomb
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Bausch + Lomb adquiere Technolas Perfect Vision GmbH
2. Bausch + Lomb to Acquire Technolas Perfect Vision GmbH
3. Bausch + Lomb übernimmt Technolas Perfect Vision GmbH
4. Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH
5. Farmers team with scientists to make the perfect rat trap
6. Nutrient and toxin all at once: How plants absorb the perfect quantity of minerals
7. Infrared vision in a cichlid fish
8. New study sheds light on how and when vision evolved
9. Military vision research symposium focuses on visual fallout from war
10. Deep-sea crabs seek food using ultraviolet vision
11. IdentiSys acquires the Identification, Security and Presentation Divisions of Mountainland Business Systems, a Utah based reseller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... in the brain may unlock the mystery behind the ... issue of Cell. Hibernation allows animals from bears to ... the harshest of winter conditions. , If the findings ... first essential brain signal governing the seasonal adaptation, according ...
... amino acid supplement L-arginine following a heart attack does ... be associated with an increased risk of death, according ... JAMA. , L-arginine is a widely available dietary supplement ... hypertension, angina, heart failure and sexual dysfunction, according to ...
... "biobullet" that could help control an invasive mollusk that ... water pipes, virtually wiping out some native mussels species ... new microcapsules, which contain toxins that dissolve within a ... way of eliminating one of the world's "most important ...
Cached Biology News:Possible brain hormone may unlock mystery of hibernation 2Possible brain hormone may unlock mystery of hibernation 3Use of amino acid supplement following a heart attack provides no benefit, may be harmful 2'Biobullets' fight harmful mussels 2
(Date:4/21/2015)... 2015 Staying true to their mission ... digital product that makes the world a better place, ... Standards Institute (GBSI) to redesign their website ( http://www.gbsi.org ... importantly, strategy-based. , "Biomedical research is not always an ... to promote it in a narrative way on a ...
(Date:4/21/2015)... YORK , April 21, 2015 AbilTo, ... today that its abstract submission has been accepted as ... Association,s (ADA) annual meeting taking place on June 5-6, 2015 ... According to the American Diabetes Association, the cost ... was $245 billion. As a result of increased inpatient, ...
(Date:4/21/2015)... 2015 Invetech , a global ... and contract manufacturing, and  NanoCellect Biomedical, a ... cell sorting technology for life science researchers, today ... cytometry platform. Headquartered in ... a microchip-based cell sorting technology. NanoCellect,s flow cytometry ...
(Date:4/21/2015)... 21, 2015 Immune Pharmaceuticals Inc., or "Immune" ... Directors has elected Rene-Pierre Azria as a ... Committee, with oversight on strategic and financial transactions. Mr. ... Committee, the Compensation Committee and the Corporate Governance and ... commented: "I have a long-time interest in Life Sciences ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4
... , , MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ ... TSX: YM), a life sciences product development company that ... products at various stages of development, today reported that ... trial evaluating CYT387, a potent, orally-administered JAK1/JAK2 inhibitor. The ...
... , , SEATTLE, Nov. ... Bruce L.A. Carter has joined IDC as Executive Chairman. ... management. He was the former Chief Executive Officer at ... Nordisk, Copenhagen, Denmark. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091123/SF15228 ) ...
... , REDWOOD CITY, Calif., Nov. ... therapeutic products for the treatment of chronic respiratory diseases, ... company,s Board of Directors. Mr. Rosen has 25 years ... key roles at Gilead Sciences and ALZA Corporation. His ...
Cached Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 5Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2
...
...
...
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
Biology Products: